help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WEERSINK, E. J. M.
Right arrow Articles by POSTMA, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WEERSINK, E. J. M.
Right arrow Articles by POSTMA, D. S.

Am. J. Respir. Crit. Care Med., Volume 156, Number 4, October 1997, 1144-1150

Treatment of Nocturnal Airway Obstruction Improves Daytime Cognitive Performance in Asthmatics

ELS J. M. WEERSINK, ED H. van ZOMEREN, GERARD H. KOËTER, and DIRKJE S. POSTMA

Department of Pulmonology, and Department of Neurology University Hospital Groningen, The Netherlands

It has been shown that asthmatics have nocturnal symptoms associated with impaired cognitive performance. We explored more carefully different therapeutic approaches on this performance in relation to lung function in 46 atopics with mild to moderate asthma and with a circadian variation in peak expiratory flow (PEF) >=  15%. In a double-blind, parallel study they inhaled salmeterol 50 µg or fluticasone 250 µg or a combination of both twice daily for 6 wk. The psychometric tests used informed about focused attention, mental flexibility, concentration, and attention. The results of the psychometric tests were compared with those in healthy control subjects. The PASAT score and the finishing time of the color-word chart subtest were significantly lower in these asthmatics than in the control subjects. Circadian PEF variation was the only independent factor significantly associated with impaired cognitive performance before the treatment period. The three treatment groups were equally effective in reducing circadian PEF variation below 10% and in improving FEV1 and bronchial hyperresponsiveness to methacholine (MCh) both day and night. After 6 wk of therapy, the daytime cognitive performance was improved to levels comparable to those of the healthy control subjects no matter which drug was inhaled. We conclude that a high level of circadian PEF variation (>=  20%) has been associated with lower daytime cognitive performance in asthmatics. Reduction of circadian PEF variation to below 10% is an important goal of treatment in asthmatics.




This article has been cited by other articles:


Home page
 Psychosom. Med.Home page
M. Richards, D. Strachan, R. Hardy, D. Kuh, and M. Wadsworth
Lung Function and Cognitive Ability in a Longitudinal Birth Cohort Study
Psychosom Med, July 1, 2005; 67(4): 602 - 608.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
L. Bentur, R. Beck, M. Shinawi, T. Naveh, and N. Gavriely
Wheeze monitoring in children for assessment of nocturnal asthma and response to therapy
Eur. Respir. J., April 1, 2003; 21(4): 621 - 626.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
W. J. Calhoun
Nocturnal Asthma
Chest, March 1, 2003; 123(2007): 399S - 405S.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1997 American Thoracic Society 		  2009/2010 ATS Fellows Career Development Awards